<p>Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - 获取免费报告) 被四家研究公司给予&#34;买入&#34;评级，Marketbeat 报告称。四位股票研究分析师对该股票给出了买入建议。过去一年发布关于该股票报告的经纪公司中，平均一年目标价格为 8.25 美元。</p>
<p>获取 <strong>Amneal Pharmaceuticals</strong> 警报：</p>
<ul>
<li>6 个购买 Teva Pharmaceuticals 股票的理由</li>
</ul>
<p>几位分析师最近对 AMRX 股票发表了评论。Truist Financial 重申了&#34;买入&#34;评级，并在 5 月 6 日星期一的报告中发布了 9.00 美元的价格目标（从 7.00 美元上调）。高盛集团将 Amneal Pharmaceuticals 的价格目标从 6.25 美元上调至 8.00 美元，并给予该公司&#34;买入&#34;评级。StockNews.com 在 3 月 4 日星期一的报告中，将 Amneal Pharmaceuticals 的评级从&#34;强烈买入&#34;调降为&#34;买入&#34;。最后，Piper Sandler 将 Amneal Pharmaceuticals 的价格目标从 6.00 美元上调至 8.00 美元，并给予该公司&#34;超配&#34;评级。</p>
<p><strong>查看我们对 AMRX 的最新分析</strong></p>
<h2>对 Amneal Pharmaceuticals 的对冲基金意见</h2>
<p>一些大型投资者最近增加或减少了他们在该股票中的持股。Vanguard Group Inc. 在第一季度将其在 Amneal Pharmaceuticals 的持股比例提高了 0.6%。Vanguard Group Inc. 现在拥有公司股票的 13,728,233 股，价值 831,930,000 美元，在此期间增加了 85,846 股。Rubric Capital Management LP 在第四季度将其在 Amneal Pharmaceuticals 的持股比例增加了 98.8%。Rubric Capital Management LP 现在拥有公司股票的 8,000,000 股，价值 485,600,000 美元，在上一季度增加了 3,975,500 股。查尔斯史瓦布投资管理公司在第四季度将其在 Amneal Pharmaceuticals 的持股比例增加了 2.1%。查尔斯史瓦布投资管理公司现在拥有公司股票的 1,329,508 股，价值 80,700,000 美元，在上一季度增加了 26,875 股。德克萨斯州教师退休系统在第四季度将其在 Amneal Pharmaceuticals 的持股比例增加了 3.4%。德克萨斯州教师退休系统现在拥有公司股票的 744,752 股，价值 45,210,000 美元，在上一季度增加了 24,651 股。最后，Phocas Financial Corp. 在第四季度购入了 Amneal Pharmaceuticals 的新股份，价值 4,339,000 美元。目前有 31.82% 的股份由机构投资者和对冲基金持有。</p>
<h2>Amneal Pharmaceuticals 股价上涨 0.4%</h2>
<p>NASDAQ: AMRX 在周五开盘价为 6.75 美元。该公司的市值为 20.8 亿美元，市盈率为-12.05，β系数为 1.19。Amneal Pharmaceuticals 过去一年的最低价为 2.29 美元，最高价为 7.25 美元。该公司的流动比率为 1.65，速动比率为 0.97，负债权益比为 121.31。公司的 50 天移动平均价为 6.42 美元，200 天移动平均价为 5.88 美元。</p>
<p>Amneal Pharmaceuticals (NASDAQ: AMRX - 获取免费报告) 上次发布其财报是在 5 月 3 日星期五。该公司报告季度每股盈利为 0.12 美元，超过了 0.08 美元的共识预期 0.04 美元。该季度公司的营收为 6.5919 亿美元，超过了 6.2308 亿美元的共识预期。Amneal Pharmaceuticals 的净利润率为-6.76%，股东权益回报率为 234.06%。分析师预计，Amneal Pharmaceuticals 当年将实现每股盈利 0.51 美元。</p>
<h2>关于 Amneal Pharmaceuticals（获取免费报告）</h2>
<p>Amneal Pharmaceuticals, Inc.及其子公司在全球范围内开发、制造、销售和分销仿制药、注射剂、生物类似药和特殊品牌药品。该公司通过三个部门运营：仿制药、特殊品牌和 AvKARE。仿制药部门提供即时和延长释放口服固体、粉剂、液体、无菌注射剂、鼻喷剂、吸入和呼吸、生物类似药、眼科、膜、透皮贴片和局部产品。</p>
<h2>精选文章</h2>
<ul>
<li>五支我们比 Amneal Pharmaceuticals 更喜欢的股票</li>
<li>3 家可提升您投资组合的家居装修股</li>
<li>达登股票在第四季度盈利超预期后上涨，对 2025 财年展望谨慎</li>
<li>10 家最佳航空公司股票</li>
<li>Celsius 股票：为什么派杰·桑德勒预测将大涨 50%</li>
<li>什么是日经 225 指数？</li>
<li>安永的股票收益揭示了一项基于人工智能的增长策略</li>
</ul>
<p><em>此即时新闻警报由叙事科技和来自 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 在 Nvidia 1.10 美元时发出买入建议的人士现在说买这个...（来自牛津俱乐部）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjA5"/></p>
<h2>现在是否值得投资 1000 美元购买 Amneal Pharmaceuticals？</h2>
<p>在考虑购买 Amneal Pharmaceuticals 之前，您会想听听这个。</p>
<p>MarketBeat 持续追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票... 而 Amneal Pharmaceuticals 不在名单上。</p>
<p>虽然 Amneal Pharmaceuticals 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

AMRX

<p>Amneal Pharmaceuticals（纳斯达克股票代码：AMRX）已获得四家研究公司的 “买入” 评级。该股票的 1 年目标价为 8.25 美元，并且获得了分析师的积极评价。机构投资者和对冲基金也对该股票表现出兴趣。Amneal Pharmaceuticals 报告了季度超出预期的盈利业绩</p>

<p>Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given an average rating of &#34;Buy&#34; by the four research firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.25.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - 获取免费报告) 被四家研究公司给予&#34;买入&#34;评级，Marketbeat 报告称。四位股票研究分析师对该股票给出了买入建议。过去一年发布关于该股票报告的经纪公司中，平均一年目标价格为 8.25 美元。</p>
</div><p>Get <strong>Amneal Pharmaceuticals</strong> alerts:</p>
<ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Amneal Pharmaceuticals</strong> 警报：</p>
<ul>
<li>6 个购买 Teva Pharmaceuticals 股票的理由</li>
</ul>
</div><p>Several analysts have recently commented on AMRX shares. Truist Financial reaffirmed a &#34;buy&#34; rating and issued a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday, May 6th. The Goldman Sachs Group upped their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Monday, May 6th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Monday, March 4th. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, March 21st.</p>
<div class="lb-trans"><p>几位分析师最近对 AMRX 股票发表了评论。Truist Financial 重申了&#34;买入&#34;评级，并在 5 月 6 日星期一的报告中发布了 9.00 美元的价格目标（从 7.00 美元上调）。高盛集团将 Amneal Pharmaceuticals 的价格目标从 6.25 美元上调至 8.00 美元，并给予该公司&#34;买入&#34;评级。StockNews.com 在 3 月 4 日星期一的报告中，将 Amneal Pharmaceuticals 的评级从&#34;强烈买入&#34;调降为&#34;买入&#34;。最后，Piper Sandler 将 Amneal Pharmaceuticals 的价格目标从 6.00 美元上调至 8.00 美元，并给予该公司&#34;超配&#34;评级。</p>
</div><p><strong>Check Out Our Latest Analysis on AMRX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AMRX 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Amneal Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Amneal Pharmaceuticals 的对冲基金意见</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Amneal Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company's stock worth $83,193,000 after acquiring an additional 85,846 shares during the period. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 98.8% during the fourth quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company's stock worth $48,560,000 after buying an additional 3,975,500 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Amneal Pharmaceuticals by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company's stock worth $8,070,000 after buying an additional 26,875 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Amneal Pharmaceuticals by 3.4% during the fourth quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company's stock worth $4,521,000 after buying an additional 24,651 shares in the last quarter. Finally, Phocas Financial Corp. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $4,339,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了他们在该股票中的持股。Vanguard Group Inc. 在第一季度将其在 Amneal Pharmaceuticals 的持股比例提高了 0.6%。Vanguard Group Inc. 现在拥有公司股票的 13,728,233 股，价值 831,930,000 美元，在此期间增加了 85,846 股。Rubric Capital Management LP 在第四季度将其在 Amneal Pharmaceuticals 的持股比例增加了 98.8%。Rubric Capital Management LP 现在拥有公司股票的 8,000,000 股，价值 485,600,000 美元，在上一季度增加了 3,975,500 股。查尔斯史瓦布投资管理公司在第四季度将其在 Amneal Pharmaceuticals 的持股比例增加了 2.1%。查尔斯史瓦布投资管理公司现在拥有公司股票的 1,329,508 股，价值 80,700,000 美元，在上一季度增加了 26,875 股。德克萨斯州教师退休系统在第四季度将其在 Amneal Pharmaceuticals 的持股比例增加了 3.4%。德克萨斯州教师退休系统现在拥有公司股票的 744,752 股，价值 45,210,000 美元，在上一季度增加了 24,651 股。最后，Phocas Financial Corp. 在第四季度购入了 Amneal Pharmaceuticals 的新股份，价值 4,339,000 美元。目前有 31.82% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>Amneal Pharmaceuticals Stock Up 0.4 %</h2>
<div class="lb-trans"><h2>Amneal Pharmaceuticals 股价上涨 0.4%</h2>
</div><p>NASDAQ:AMRX opened at $6.75 on Friday. The company has a market cap of $2.08 billion, a PE ratio of -12.05 and a beta of 1.19. Amneal Pharmaceuticals has a twelve month low of $2.29 and a twelve month high of $7.25. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The company's 50 day moving average is $6.42 and its two-hundred day moving average is $5.88.</p>
<div class="lb-trans"><p>NASDAQ: AMRX 在周五开盘价为 6.75 美元。该公司的市值为 20.8 亿美元，市盈率为-12.05，β系数为 1.19。Amneal Pharmaceuticals 过去一年的最低价为 2.29 美元，最高价为 7.25 美元。该公司的流动比率为 1.65，速动比率为 0.97，负债权益比为 121.31。公司的 50 天移动平均价为 6.42 美元，200 天移动平均价为 5.88 美元。</p>
</div><p>Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, May 3rd. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $659.19 million for the quarter, compared to the consensus estimate of $623.08 million. Amneal Pharmaceuticals had a negative net margin of 6.76% and a positive return on equity of 234.06%. Analysts anticipate that Amneal Pharmaceuticals will post 0.51 EPS for the current year.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals (NASDAQ: AMRX - 获取免费报告) 上次发布其财报是在 5 月 3 日星期五。该公司报告季度每股盈利为 0.12 美元，超过了 0.08 美元的共识预期 0.04 美元。该季度公司的营收为 6.5919 亿美元，超过了 6.2308 亿美元的共识预期。Amneal Pharmaceuticals 的净利润率为-6.76%，股东权益回报率为 234.06%。分析师预计，Amneal Pharmaceuticals 当年将实现每股盈利 0.51 美元。</p>
</div><h2>About Amneal Pharmaceuticals (Get Free Report</h2>
<div class="lb-trans"><h2>关于 Amneal Pharmaceuticals（获取免费报告）</h2>
</div><p>Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals, Inc.及其子公司在全球范围内开发、制造、销售和分销仿制药、注射剂、生物类似药和特殊品牌药品。该公司通过三个部门运营：仿制药、特殊品牌和 AvKARE。仿制药部门提供即时和延长释放口服固体、粉剂、液体、无菌注射剂、鼻喷剂、吸入和呼吸、生物类似药、眼科、膜、透皮贴片和局部产品。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Amneal Pharmaceuticals</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Celsius Stock: Why Piper Sandler Forecasts a 50% Surge</li>
<li>What is the Nikkei 225 index?</li>
<li>Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五支我们比 Amneal Pharmaceuticals 更喜欢的股票</li>
<li>3 家可提升您投资组合的家居装修股</li>
<li>达登股票在第四季度盈利超预期后上涨，对 2025 财年展望谨慎</li>
<li>10 家最佳航空公司股票</li>
<li>Celsius 股票：为什么派杰·桑德勒预测将大涨 50%</li>
<li>什么是日经 225 指数？</li>
<li>安永的股票收益揭示了一项基于人工智能的增长策略</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和来自 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Man Who Called Nvidia at $1.10 Says Buy This Now... (From The Oxford Club)(Ad)</p>
<div class="lb-trans"><p>→ 在 Nvidia 1.10 美元时发出买入建议的人士现在说买这个...（来自牛津俱乐部）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjA5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8209&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Amneal Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买 Amneal Pharmaceuticals？</h2>
</div><p>Before you consider Amneal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Amneal Pharmaceuticals 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 持续追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票... 而 Amneal Pharmaceuticals 不在名单上。</p>
</div><p>While Amneal Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amneal Pharmaceuticals 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Amneal Pharmaceuticals, Inc.（纳斯达克股票代码：AMRX）被分析师一致评为 “买入”